R4 Ballot #1 #2 (Mixed Normative/Trial use)

This page is part of the FHIR Specification (v3.3.0: (v3.5.0: R4 Ballot 2). #2). The current version which supercedes this version is 5.0.0 . For a full list of available versions, see the Directory of published versions . Page versions: R4 R3

4.3.2.16621 4.4.2.16621 HL7 v3 Value Set ActSubstanceAdminSubstitutionCode

Vocabulary Work Group   Maturity Level : 1 Draft Use Context : Any

This value set (http://hl7.org/fhir/ValueSet/v3-ActSubstanceAdminSubstitutionCode) (http://terminology.hl7.org/ValueSet/v3-ActSubstanceAdminSubstitutionCode) is defined as part of HL7 v3. Related FHIR content: ActSubstanceAdminSubstitutionCode .

Summary

Defining URL: http://hl7.org/fhir/ValueSet/v3-ActSubstanceAdminSubstitutionCode http://terminology.hl7.org/ValueSet/v3-ActSubstanceAdminSubstitutionCode
Version: 2014-03-26
Name: ActSubstanceAdminSubstitutionCode v3.ActSubstanceAdminSubstitutionCode
Title: V3 Value SetActSubstanceAdminSubstitutionCode
Definition:

No Description Provided

OID: 2.16.840.1.113883.1.11.16621 (for OID based terminology systems)
Source Resource XML / JSON

This value set is used in the following places:

4.3.2.16621.1 4.4.2.16621.1 Content Logical Definition

This value set includes codes from the following code systems:

 

4.3.2.16621.2 4.4.2.16621.2 Expansion

This expansion generated 03 Apr 19 Aug 2018

This value set contains 9 concepts

Expansion based on http://hl7.org/fhir/v3/substanceAdminSubstitution http://terminology.hl7.org/CodeSystem/v3-substanceAdminSubstitution version 2018-04-01 2018-08-12

All codes from system http://hl7.org/fhir/v3/substanceAdminSubstitution http://terminology.hl7.org/CodeSystem/v3-substanceAdminSubstitution

Code Display Definition
E equivalent Description: Substitution occurred or is permitted with another bioequivalent and therapeutically equivalent product.
EC equivalent composition Description: Substitution occurred or is permitted with another product that is a: pharmaceutical alternative containing the same active ingredient but is formulated with different salt, ester pharmaceutical equivalent that has the same active ingredient, strength, dosage form and route of administration Examples: Pharmaceutical alternative: Erythromycin Ethylsuccinate for Erythromycin Stearate Pharmaceutical equivalent: Lisonpril for Zestril
BC brand composition Description: Substitution occurred or is permitted between equivalent Brands but not Generics Examples: Zestril for Prinivil Coumadin for Jantoven
G generic composition Description: Substitution occurred or is permitted between equivalent Generics but not Brands Examples: Lisnopril (Lupin Corp) for Lisnopril (Wockhardt Corp)
TE therapeutic alternative Description: Substitution occurred or is permitted with another product having the same therapeutic objective and safety profile. Examples: ranitidine for Tagamet
TB therapeutic brand Description: Substitution occurred or is permitted between therapeutically equivalent Brands but not Generics > Examples: Zantac for Tagamet
TG therapeutic generic Description: Substitution occurred or is permitted between therapeutically equivalent Generics but not Brands > Examples: Ranitidine for cimetidine
F formulary Description: This substitution was performed or is permitted based on formulary guidelines.
N none No substitution occurred or is permitted.